Drug Database
Back to search

Poland· PL-100029288

Holoxan

A ifosfamide product containing ifosfamidum, registered in Poland by Baxter Polska Sp. z o.o.. The same ATC class is registered in 15 of our 19 countries.

ATC L01AA06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedHoloxanATCL01AA06REGISTER NO.PL-100029288PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ifosfamidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ifosfamide is registered in 15 of 19 countries.

Countries holding a registration under ATC L01AA06 (ifosfamide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search ifosfamide products by name

Ifosfamide · ATC L01AA06

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ifosfamide costs, country by country.

Normalised to the WHO defined daily dose (0.7 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ifosfamide · price per daily dose (0.7 g)

USD · FX 28 Sept 2026

  • CH Switzerland$52.67
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Ifosfamidum
Manufacturer
Baxter Polska Sp. z o.o.
Country
Poland (PL)
ATC code
L01AA06
ATC class
Ifosfamide
Defined daily dose
0.7 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990241224
  • gtin
    05909990241217

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

514 interactions on record for ifosfamide.

Graded by severity as the source publishes them — 41 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ifosfamide against other medicinesHow interaction checks work

Ifosfamide · interactions on record

514 records

  • 41 severe
  • 385 moderate
  • 16 minor
  • 72 info

Most severe, free to view

  • Nalidixic acidJ01MB02severe
  • CidofovirJ05AB12severe
  • ThiotepaL01AC01severe
  • CladribineL01BB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ifosfamide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ifosfamide products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Holoxan
  • Belgium · Holoxan
  • Bulgaria · Холоксан
  • Czechia · Holoxan
  • Germany · Holoxan, Ifo-Cell
  • Denmark · Holoxan
  • Estonia · Holoxan
  • Spain · Tronoxal
  • Finland · Holoxan
  • France · Holoxan, Ifosfamide Eg
  • United Kingdom (Northern Ireland) · Ifosfamide Baxter Healthcare
  • Greece · Holoxan
  • Croatia · Holoxan
  • Hungary · Holoxan
  • Ireland · Mitoxana
  • Iceland · Holoxan
  • Italy · Holoxan
  • Lithuania · Holoxan
  • Luxembourg · Holoxan
  • Latvia · Holoxan
  • Malta · Mitoxana
  • Netherlands · Holoxan
  • Norway · Holoxan
  • Portugal · Holoxan
  • Romania · Holoxan
  • Sweden · Holoxan
  • Slovenia · Holoxan
  • Slovakia · Holoxan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ec898794-6ca2-4cab-b446-e61836c76267
GET /v1/drugs/ec898794-6ca2-4cab-b446-e61836c76267?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "2 g",
  "packaging": "05909990241224 ¦ Lz ¦ 4664\n10 fiol.  proszku\n05909990241217 ¦ Lz ¦ 46342\n1 fiol.  proszku",
  "substance": "Ifosfamidum 2000 mg",
  "common_name": "Ifosfamidum",
  "pl_product_id": "100029288",
  "pozwolenie_nr": "02412",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about ifosfamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console